1. The Company tests impairment of goodwill on an annual basis. Based on the annual impairment test no provision towards impairment was required necessary. The recoverable amounts determined based on value-in-use calculations which is calculated as the net present value of forecasted cash flows of the cash generating unit (CGU) to which the goodwill is related. Acquired brands are considered as CGU for testing impairment of goodwill amounting to Rs 48.57 crores generated on acquisition of brands.

2. The key assumptions for CGUs with significant amount of goodwill as follows:

Projected cash flows for five years based on financial budgets/forecasts in line with the past experience. The terminal value has been determined using a long-term growth rate of 5%, which reflects expected macroeconomic growth factors. The discount rate, determined as 12% as of March 31, 2025, is based on current market conditions and the specific circumstances of the Company and its operations. It has been derived from the Company's weighted average cost of capital (WACC). The Management believes that any reasonable possible change in the key assumptions on which a recoverable amount is based would not cause the carrying amount to exceed its recoverable amount of the CGU.

3.1 Lock in period for Eris M. J. Biopharm Private Limited

As per share purchase & shareholders agreement, For a period of 10 (ten) years , Eris Lifesciences Limited and M.J. Biopharm Private Limited shall not, directly or indirectly, transfer or attempt to transfer all or any of the Equity Shares (or any interest therein) held by it to any Person.

3.2 Details of perpetual securities:

During the previous year/s, the company has invested in unsecured subordinated perpetual securities issued by Aprica Healthcare Limited . These securities are redeemable at the issuer's option and carry non-cumulative interest coupon at the rate of dividend paid on the issuer's ordinary shares. No interest will be payable if the issuer does not pay any dividend on its ordinary shares for the Financial Year. The issuer has classified these instruments as equity under Ind AS 32 Financial Instruments presentation. Accordingly, the Company has classified this investment as Equity Instrument and has accounted at cost as per Ind AS 27 Separate Financial Statements. During the current year issuer have redeemed such securities.

3.3 During the year, the Company has sold it's investment in Equity share capital, Preference Share capital and Compulsory Convertible Debentures of Eris Oaknet Healthcare Private Limited and it's investment in Equity share capital of Aprica Healthcare Limited to Eris Therapeutics Limited for consideration of Rs. 872.19 Crore being the Carrying amount in the books of account of the Company. Out of the total consideration the Company has received Rs. 240 Crore during the current financial year.

3.4 As of March 31, 2025, out of the total 39,07,145 equity shares of Swiss Parenterals Limited (SPL), 22,32,657 equity shares were pledged with debenture trustees as security for Non-Convertible Debentures (NCDs) amounting to '437.50 crore, which were issued to the erstwhile shareholders of SPL. These debentures were fully redeemed during the current financial year. The Company is currently in the process of initiating the release of the pledged equity shares held by the debenture trustees.

I. 4 Terms / Rights attached to the equity shares:

The Company has only one class of equity shares having a par value of Rs 1 per share. Each holder of equity share is eligible for one vote per share. The final dividend, if any, proposed by the Board of Directors of the Company is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

II. 5 Share options granted under the Company's employee share option plan:

The Company recognizes compensation expense relating to share-based payments in statement of profit and loss using fair value in accordance with Ind AS 102, share based payment. The estimated fair value of awards is charged to income on a straightline basis over the requisite service period for each separately vesting portion of the award as if the award was in-substance multiple awards with a corresponding increase to share options outstanding account.

11.6 Dividend

The Board of Directors of the Company has declared and paid an interim dividend of Rs 7.35/- (at the rate of 735 Percent) per equity share of the face value of Rs 1/- each for the financial year 2024-25 at its meeting held on February 07, 2025.

Nature and purpose of reserves :

Retained Earnings: Retained Earnings are the profits that the company has earned till date less any transfer to general reserve, dividends and other distributions to shareholder.

Share based payment reserve : The fair value of equity-settled share based payment transactions with employees is recognised in Statement of Profit and Loss with corresponding credit to Share based payment reserve. Such amount is available for utilisation in accordance with the provisions of the Companies Act, 2013.

Capital redemption reserve: The Company is required to create capital redemption reserve in accordance with provisions of the Companies Act 2013 for buy back of shares. The reserve can be utilised in accordance with the provisions of section 69 of the Companies Act, 2013.

Security premium: The amount received in excess of the par value of equity shares has been classified as securities premium. Such amount is available for utilisation in accordance with the provisions of the Companies Act, 2013.

Provision for sales returns:

The Company, as a trade practice, accepts returns from market which includes claims for product expiry, near expiry, damages and return of goods. Provision is made for such returns on the basis of historical experience, market conditions and specific contractual terms.

At the time of recognising provision for sales return expected reimbursement towards likely sales return is also recognised, which is included in other current assets for the products expected to be returned.

Trade receivables are non-interest bearing and are generally on terms of 7 to 90 days. As at March 2025 Rs 16.70 Crores (March 2024: Rs 7.90 Crores) was recognised as provision for doubtful debts and expected credit losses.

Advance from customers includes short term advance received for sale of products

Contract assets are initially recognised for revenue from sale of goods. Contract liabilities are on account of the upfront revenue received from customer for which performance obligation has not yet been completed.

The performance obligation is satisfied when control of the goods or services are transferred to the customers based on the contractual terms. Payment terms with customers vary depending upon the contractual terms of each contract.

Note 26: Segment reporting

Operating segments are defined as components of an enterprise for which discrete financial information is available that is evaluated regularly by the chief operating decision maker (CODM), in deciding how to allocate resources and assessing performance. The Company's chief operating decision maker is the managing director and the company has only one reportable business segment i.e. 'pharmaceuticals'.

Note 27: Business Combinations

Note 27.1: Acquisition of the Branded Formulations India business units Insulin, Oncology and Critical Care products from Biocon Biologics Limited

During the current year, the Company has completed acquisition of the Indian Branded Formulations business comprising of Insulin, Oncology and Critical Care products from Biocon Biologics Limited for a consideration of Rs. 1,242 crore on a slump sale basis. The acquisition was completed on April 1, 2024. The Company has determined the fair values of identified assets and liabilities for the purpose of Purchase price allocation. The figures of the current period are not comparable with those of corresponding period included in the aforesaid statement due to said acquisition.

Goodwill arose in the acquisition of the above said entity because the consideration paid for the combinations effectively included amounts in relation to the benefit of expected synergies, revenue growth, future market development and the assembled workforce. These benefits are not recognised separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets.

Note 27.2: Acquisition of 19% shares of Swiss Parenterals Limited

During the previous year, the Company completed the acquisition of 28,46,639 equity shares of Rs.10 each of Swiss Parenterals Limited (SPL) representing 51% of equity share capital for an aggregate consideration of Rs. 638.30 crore (including transaction cost) of SPL and obtained control on February 15, 2024 from its erstwhile shareholders. During the current year, the Company has further acquired 10,60,512 equity shares of Rs 10 each of SPL representing 19% of the equity share capital of SPL on April 18, 2024 for a consideration of Rs. 237.50 crore from the promoters of the Company at the same per equity share price as paid to erstwhile shareholders.

Note 27.3: Acquisition of 100% Shares in Eris Bionxt Private Limited (formerly known as Chemman Labs Private Limited)

During the current year, the Company acquired 1,43,13,418 equity shares of Rs 10 each representing 100% of the equity share capital of Eris Bionxt Private Limited (formerly known as Chemman Labs Private Limited) from its erstwhile shareholders for a consideration of Rs. 27 Crores. The transaction achieved closure in October 2024, on completion of all relevant conditions precedent to the transaction.

Note 27.4: Acquisition of 100% equity shares of Eris Pharmaceuticals Limited (formerly known as Eris Pharmaceuticals Private Limited)

During the current year, the Company has acquired 10000 equity shares of Eris Pharmaceuticals Limited (EPL) at the face value of Rs 10 from the erstwhile shareholders, thereby EPL has become a wholly- owned subsidiary of the Company. Before the acquisition date EPL was step down subsidiary of the Company.

Note 27.5: Acquisition of the Branded Formulations India business units of Nephrology and Dermatology from Biocon Biologics Limited

During the previous year, the Company has completed acquisition of the Branded Formulations India business units of Nephrology and Dermatology from Biocon Biologics Limited for a consideration of Rs 366 Crores on a slump sale basis. The acquisition was completed on November 9, 2023. The Company has determined the fair values of identified assets and liabilities for the purpose of Purchase price allocation.

The acquisition has been accounted for using the acquisition method of accounting.

Goodwill arose in the acquisition of the above said entity because the consideration paid for the combinations effectively included amounts in relation to the benefit of expected synergies, revenue growth, future market development and the assembled workforce. These benefits are not recognised separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets.

None of the goodwill is expected to be deductible for income tax purposes.

Note 27.6: Demerger of Domestic Business of Eris Oaknet Healthcare Private Limited (EOHPL)

During the previous financial year, the Company had proposed a Composite Scheme of Arrangement which involved the demerger of the domestic formulation business of EOHPL and its merger into the Company . As mentioned in note 3.3, Eris Lifesciences Limited has sold it's equity investment in Eris Oaknet Healthcare Private Limited (EOHPL) to Eris Therapeutics Limited (ETL).

As a result, EOHPL is a now a wholly owned subsidiary of ETL.

After the close of the current financial year, taking into account the revised shareholding structure and other relevant factors arising from the above-mentioned transfer of stake, the Company decided to revise and modify the earlier proposed Scheme whereby the "Domestic Business" of Eris Oaknet Healthcare Private Limited shall get vested into Eris Therapeutics Limited ("Resulting Company/Amalgamated Company") and Aprica Healthcare Limited ("Amalgamating Company", "AHL") would be amalgamated with the Eris Therapeutics Limited.

Accordingly, the respective Boards of Directors of ETL, AHL, and EOHPL have approved the revised Composite Scheme of Arrangement under Sections 230 to 232, read with Section 66 and other applicable provisions of the Companies Act, 2013. The

revised Scheme is subject to necessary statutory and regulatory approvals, including approvals from shareholders, creditors, and relevant authorities, as required under applicable laws.

Note 28: Employee benefit plans

A) Defined contribution plans:

The Company makes contributions towards provident fund, a defined contribution retirement benefit plan for qualifying employees. The provident fund is operated by the Regional Provident Fund Commissioner. The Company recognized Rs. 10.16 Crore (Previous Year Rs.11.27 Crore) for provident fund contributions in the Statement of Profit and Loss. The contributions payable to these plans by the company are at rates specified in the rules of the scheme.

The Company made contributions towards Employees State Insurance Scheme operated by the ESIC Corporation. The Company recognized Rs.0.05 Crore (Previous year Rs.0.2 Crore) for ESIC contributions in the Statement of Profit and Loss. The contributions payable to these plans by the company are at rates specified in the rules of the scheme.

B) Defined benefit plans:

Actuarial Valuation for Compensated Absences is done as at the year end and the provision is made as per Company rules with corresponding charge to the Statement of Profit and Loss amounting to Rs 3.62 Crore (Previous Year Rs.4.01 Crore) and it covers all regular employees. Major drivers in actuarial assumptions, typically, are years of service and employee compensation.

The company makes annual contributions to the Employee's Group Gratuity cash accumulation scheme of the Life Insurance Corporation of India, a funded defined benefit plan for qualifying employees. The Scheme provides for payment to vested employees at retirement/death while in employment or on termination of employment as per the provisions of the Gratuity Act, 1972. The Company has Employees group gratuity trust funds which handles the payments to be made to the vested employees as per the scheme. The trust makes payment to the vested employees based on the claims raised and received from LIC. The present value of the defined benefit obligation and the related current service cost are measured using the Projected Unit Credit Method as per actuarial valuation carried out at the balance sheet date.

(ii) Fair value hierarchy:

Financial assets and financial liabilities measured at fair value in the statement of financial position are grouped into three levels of a fair value hierarchy. The three levels are defined based on the observability of significant inputs to the measurement, as follows:

Level 1: Quoted prices (unadjusted) in active markets for financial instruments.

Equity investments : Fair value of Equity investments traded in an active market are determined by reference to their quoted market prices. Other equity investments where quoted prices are not available, fair values are determined by reference to the current market value of net assets or relied upon on valuation report of an valuer.

(iii) Financial risk management:

The Company's activities are exposed to variety of financial risks. These risks include market risk, credit risk and liquidity risk. The Company's overall risk management program seeks to minimize potential adverse effects on the financial performance of the Company through established policies and processes which are laid down to ascertain the extent of risks, setting appropriate limits, controls, continuous monitoring and its compliance.

a) Market risk :

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of change in market prices. The Company is not an active investor in equity markets; it continues to hold certain investments in equity for long term value accretion. Market risk comprises of three type of risks namely interest rate risk, currency risk and other price risk such as equity price risk. The Company is not exposed to currency risk and other price risk whereas the exposure to interest risk is given below:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of change in market interest rate.

The Company invests in mutual fund schemes of leading fund houses and tax free bonds. Such investments are susceptible to market price risk that arise mainly from changes in interest rate which may impact the return and value of such investments. Investments in tax free bonds amounts to Rs.0.33 Crore and Rs.0.33 Crore as at March 31, 2025 and March 31, 2024 respectively.

b) Credit Risk

The Company is exposed to credit risk, which is the risk that counterparty will default on its contractual obligation resulting in a financial loss to the Company. Credit risk arises majorly from cash and cash equivalents, deposits with banks, Investments as well as credit exposures to customers including outstanding receivables.

Credit Risk Management

Credit risk is the risk of financial loss to the Company if a customer or counter-party fails to meet its contractual obligations, and arises principally from the companies receivables from customers.

Credit risk arises from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Company periodically assesses the financial reliability of customers, taking into account their financial position, past experience and other factors. The Company manages credit risk through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business.

Historical trends of impairment of trade receivables do not reflect any significant credit losses. Given that the macro economic indicators affecting customers of the Company have not undergone any substantial change, the Company expects the historical trend of minimal credit losses to continue.

Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk is Rs.1,245.58 Crore and Rs.1,599.98 Crore as at March 31, 2025 and March 31, 2024 respectively, being the total of the carrying amount of balances with banks, bank deposits, trade receivables, other financial assets, loans and investments excluding equity investments in subsidiaries, and these financial assets are of good credit quality including those that are past due.

Expected credit losses are measured at an amount equal to the 12 months expected credit losses or at an amount equal to the life time expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. The Company has used a practical expedient by computing the expected credit loss allowance for trade receivables based on a provision matrix. The provision matrix considers historical credit loss experience and is adjusted for forward looking information.

c) Liquidity Risk

Liquidity Risk is the risk that the company will not be able to meet its financial obligation as they fall due. Liquidity risk arises because of the possibility that the company could be required to pay its liabilities earlier than expected or encounters

difficulty in raising funds to meet commitments associated with financial liabilities as they fall due. The company approach to managing liquidity is to ensure, as far as possible, that it always have sufficient liquidity to meet its liabilities when due. The Company generates cash flows from operations to meet its financial obligations and manages liquidity risk by maintaining sufficient cash and bank balance and availability of funding through adequate amount of committed credit facilities. Contractual maturities of significant financial liabilities are mentioned below. The amounts disclosed in the table are the contractual undiscounted cash flows:

(iv) Capital management

The capital structure of the Company consists of equity, debt, cash and cash equivalents. The Company's objective for capital management is to maintain the capital structure which will support the Company's strategy to maximize shareholder's value, safeguarding the business continuity and help in supporting the growth of the Company.

The Company manages its capital structure and makes adjustments to it in the light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using Debt-Equity ratio, which is net debt divided by total equity. Debt is defined as liabilities comprising interest-bearing loans and borrowings, lease liabilities less cash and bank balances.

(v) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. As at March 31, 2025, the Company has floating rate borrowings. The Company constantly monitors the credit markets and rebalances its financing strategies to achieve an optimal maturity profile and financing cost.

For the year ended 31 March 2025, every 1% increase or decrease in the floating interest rate component (i.e., Treasury bill/Repo rate) applicable to its borrowings would affect the Company's profit before tax and Equity by Rs 8.20 Crores. (Previous year Rs 5.54 Crores.)

(vi) Foreign currency risk

The Company is exposed to foreign exchange risk arising from foreign currency transactions, primarily with respect to the EURO.

Foreign exchange risk arises from recognised assets and liabilities denominated in a currency that is not the Company's functional currency. The Company's operations in foreign currency creates natural foreign currency hedge. This results in insignificant net open foreign currency exposures considering the volumes and operations of the Company.

Foreign currency risk exposure:

* Key Managerial Personnel who are under the employment of the Company are entitled to post-employment benefits and other long term employee benefits recognised as per Ind AS 19 - 'Employee Benefits' in the financial statements. As these employee benefits are lump sum amounts provided on the basis of actuarial valuation, the same is not included above.

The above disclosure of related party transactions does not include dividend payments, as these are not considered related party transactions under the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) (Sixth Amendment) Regulations, 2021 as these payments are considered corporate actions uniformly applicable to all shareholders.

Estimated amount of contracts remaining unexecuted on capital account (net of advances) not provided:

a) Current year Rs NIL for Property Plant & Equipment (Previous year Rs 0.06 Crore)

b) Current year Rs NIL for acquisition of additional equity shares (Previous year Rs 237.5 Crore)

c) Current year Rs NIL for acquisition of business. (Previous year Rs 1,242 Crore)

The Company has given corporate guarantee to bank for credit facilities upto Rs 555 Crores (PY Rs 305 Crores) availed by its subsidiary Eris Therapeutics Limited. As per the terms of deed of guarantee, the Company undertakes not to divest its ownership interest directly or indirectly in the subsidiary and provide such managerial, technical and financial assistance to ensure continued successful operations of the subsidiary.

The Company has given corporate guarantee to bank for credit facilities upto Rs 100 Crores availed by its subsidiary Eris Healthcare Private Limited. As per the terms of deed of guarantee, the Company undertakes not to divest its ownership interest directly or indirectly in the subsidiary and provide such managerial, technical and financial assistance to ensure continued successful operations of the subsidiary.

The Company does not expect any outflow of resources in respect of the above.

Note 35: ESOP

The employee compensation cost as per fair value method for the financial year 2024-25 is Rs 9.13 Crores and for financial year 2023-24 is Rs 3.29 Crores.

A. Eris Lifesciences Employee Stock Option Plan 2017' (“ESOP 2017"/ "Plan")

The Company has introduced 'Eris Lifesciences Employee Stock Option Plan 2017' ("ESOP 2017”/ "Plan”) through the resolution passed by the Board of Directors on February 02, 2017 and the same was approved by the shareholders at the extra ordinary general meeting held on February 03, 2017 and subsequently in the eleventh annual general meeting held on September 29, 2017 shareholders ratified the same. Under the scheme, 391,599 equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of Rs 1 each for an exercise price of Rs 451.04. Vesting of the options shall take place over a maximum period of 5 years with a minimum vesting period of 1 year from the date of grant i.e. April 12, 2017. The exercise period would be a maximum of 5 years from the date of vesting of options. 1,21,430 and 1,15,783 options have lapsed till March 31, 2025 and March 31, 2024 respectively.

As per the Scheme, the Nomination and Remuneration Committee grants the options to the employees deemed eligible. Pricing Formula

Discount to fair market value of the Equity Shares as on the date of grant.

Method used for accounting of share-based payment plans

The employee compensation cost has been calculated using Black Scholes Option Pricing Model. The assumptions are as stated in the below table.

B. Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan")

The Company has introduced 'Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan") through the resolution passed by the Board of Directors on July 29, 2021 and the same was approved by the shareholders at the annual general meeting held on September 01, 2021. Under the scheme 13,58,630 equity shares have been approved in Annual General Meeting out of which, 2,14,102 equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of Rs 1 each for an exercise price of Rs 557.24. Vesting of the options shall take place over a maximum period of 4 years with a minimum vesting period of 1 year from the date of grant i.e. February 10, 2022. The exercise period would be a maximum of 7 years from the date of vesting of options.

As per the Scheme, the Nomination and Remuneration Committee grants the options to the employees deemed eligible. Pricing Formula

Discount to fair market value of the Equity Shares as on the date of grant.

Method used for accounting of share-based payment plans

The employee compensation cost has been calculated using Black Scholes Option Pricing Model. The assumptions are as stated in the below table.

C. Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan")

The Company has introduced 'Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan") through the resolution passed by the Board of Directors on July 29, 2021 and the same was approved by the shareholders at the annual general meeting held on September 01, 2021. Under the scheme 13,58,630 equity shares have been approved in Annual General Meeting out of which, 2,79,568 equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of Rs 1 each for an exercise price of Rs 510.32. Vesting of the options shall take place over a maximum period of 4 years with a minimum vesting period of 1 year from the date of grant i.e. February 10, 2023. The exercise period would be a maximum of 7 years from the date of vesting of options.

As per the Scheme, the Nomination and Remuneration Committee grants the options to the employees deemed eligible. Pricing Formula

Discount to fair market value of the Equity Shares as on the date of grant.

Method used for accounting of share-based payment plans

D. Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan")

The Company has introduced 'Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan") through the resolution passed by the Board of Directors on July 29, 2021 and the same was approved by the shareholders at the annual general meeting held on September 01, 2021. Under the scheme 13,58,630 equity shares have been approved in Annual General Meeting out of which, 2,81,761 equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of Rs 1 each for an exercise price of Rs 728.16. Vesting of the options shall take place over a maximum period of 4 years with a minimum vesting period of 1 year from the date of grant i.e. February 10, 2024. The exercise period would be a maximum of 7 years from the date of vesting of options.

As per the Scheme, the Nomination and Remuneration Committee grants the options to the employees deemed eligible. Pricing formula

Discount to fair market value of the Equity Shares as on the date of grant.

Method used for accounting of share-based payment plans

(1) Debt represents borrowings and lease liabilities.

(2) Net Profit after tax" means reported amount of "Profit / (loss) for the period" and it does not include items of other comprehensive income.

Earning for Debt Service = Net Profit after taxes Non-cash operating expenses like depreciation and other amortizations Interest other adjustments like loss on sale of Fixed assets etc."

(3) Lease payments, interest and principal repayment for the current year

(4) Tangible net worth deferred tax liabilities Lease Liabilities

Note 37 (B) : Other statutory information

i) . The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign e

ntities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (ultimate beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries

ii) . The Company has not received any fund from any person(s) or entity(ies), including foreign entities (funding party) with

the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (ultimate beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

iii) . Quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in

agreement with the unaudited books of accounts.

iv) . The title deeds of all the immovable properties, (other than immovable properties where the Company is the lessee and

the lease agreements are duly executed in favour of the Company) disclosed in the financial statements included in property, plant and equipment are held in the name of the Company as at the balance sheet date.

v) . The Company does not have any transactions or balances with a Companies struck off under section 248 of the

Companies Act, 2013 or Section 560 of the Companies Act 1956.

vi) . The Company does not have any such transaction which is not recorded in the books of accounts that has been

surrendered or disclosed as income during the year in the tax assessment under the Income Tax Act, 1961.

vii) . Details of Loan given, Investment made and Guarantee given covered u/s 186 (4) of the Companies Act, 2013:

(a) Loan given by the Company to body corporate as at March 31, 2025. (Refer Note 10)

(b) Investment made by the Company as at March 31, 2025. (Refer Note 3)

(c) Guarantee given by the Company as at March 31, 2025. (Refer note 33)

viii) The borrowings obtained by the Company from banks have been applied for the purposes for which such loans was taken.

ix) No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

x) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

xi) The Company has complied with the number of layers prescribed under the Companies Act, 2013

xii) The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.

xiii) The company has not revalued its property, plant and equipment during the current or previous year.

xiv) There are no charges or satisfaction which are yet to be registered with the Registrar of Companies beyond the statutory period.

xv) The Company has used an accounting software (SAP S/4HANA) for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same was operational for all relevant transactions recorded in the software, except that, audit trail feature was not enabled for privileged access users for smooth functioning during the migration period.

During the system implementation and stabilization period of the new accounting software (SAP), as part of the system hyper-care period, privileged access was enabled for swift issue resolution. The Company has since streamlined the process for user provisioning and privileged access to ensure compliance; with a Change Control Mechanism.

The audit trail has been preserved by the Company as per the statutory requirement for record retention.

Note 37 (C) : In order to make the billing and collection operations more efficient between the Eris group entities and its channel partners, the Board of Directors of the company decided to integrate billing and collection operations into a single entity namely, Eris Healthcare Private Limited (EHPL) which is wholly owned subsidiary of Eris Lifesciences Limited w.e.f. March 2025 in a phase wise manner. As a result of the above, the domestic formulation sales from the Eris group entities shall be primarily from EHPL which in turn would deal with the channel partners.

Note 39:

The figures in the financial statements have been converted from millions to crores. Comparative figures have been updated accordingly wherever necessary.

Note 40:

The Financial Statements were approved for issue by Board of Directors on May 19, 2025.